Tyler Cowen

And there's not really another place they can go that will fit them.

I hope AI lowers costs.

As you probably know, at ARC, they had Greg Brockman come in for some number of months.

And he's one of the people, well, he helped build up Stripe, but he also was highly significant at OpenAI behind the GPT-4 model.

And to have Greg Brockman at your institute doing AI for, what, six months?

That's a massive acceleration.

But actually, no university had the wisdom to do, and ARC did.

So I think we're seeing just more entrepreneurial thinking in the area.

There's still this problem of bottlenecks.

So let's say AI is great for drug discovery, as it may be.

Well, clinical trials then become a bigger bottleneck.

The FDA becomes a bigger bottleneck.

So rapid improvement in only one area, while great, is actually not good enough.

Art can move very quickly.

I think that's not appreciated.

So if Patrick Hsu decides, you know, Silvana, Kahneman, Patrick Collison, if they decide, you know, something ought to be bought or purchased or set in motion, you know, it can happen in less than a day.

And it does happen basically immediately.

It's not only that it's quicker.

I think when you have quicker decisions, they're better and it's infectious to the people you're working with.

There's an understanding that the core environment is not a bureaucratic one.